Trial Profile

A Phase 3a, Observer-blind, Randomized, Controlled Study to Demonstrate Lot-to-lot Consistency and Evaluate the Immunogenicity and Safety of an Investigational Varicella Vaccine Compared With Varivax, Administered as a First Dose to Healthy Children 12 to 15 Months of Age

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 09 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Varicella vaccine-GlaxoSmithKline (Primary) ; Hepatitis A vaccine; Measles mumps and rubella virus vaccine; Measles mumps and rubella virus vaccine; Pneumococcal 20-valent conjugate vaccine; Pneumococcal vaccine conjugate; V 114; Varicella vaccines
Indications Chickenpox
Focus Pharmacodynamics; Registrational
Sponsors GSK

11 Feb 2025 Planned End Date changed from 28 May 2027 to 13 May 2027.
11 Feb 2025 Planned primary completion date changed from 4 Jan 2027 to 25 Dec 2026.
11 Feb 2025 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com